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A b s t r a c t
Background and aim: The assessment of percutaneous renal sympathetic denervation (RDN) efficacy in patients with 
true-resistant hypertension (true-RH) in a newly established net of Polish centres (RDN-POL Registry).
Methods and results: Forty-four patients with true-RH (23 men, mean age 52.3 years) with daytime systolic blood pressure 
(SBP) in ambulatory blood pressure monitoring (ABPM) ≥ 135 mm Hg, on ≥ three antihypertensive agents, including diuretic, 
underwent RDN and completed 12-month follow-up. Mean reductions of office SBP/diastolic blood pressure were –23.8/–10.0, 
–12.5/–4.6, and –12.6/–6.1 mm Hg at 3, 6, and 12 months, respectively (all significant except diastolic at 6 months). Diabetes 
was the only predictor of office SBP reduction at 6 months (OR 9.6, 95% CI 1.4–66.5, p < 0.05). Mean 24-h SBP change 
was –8.3 mm Hg at 6 months and –4.6 mm Hg at 12 months. Increased 2 h-glucose in oral glucose tolerance test was the 
only predictor of 24-h SBP reduction at 6 months (OR 1.24 for 10 mg/dL glucose increase, 95% CI 1.04–1.48, p < 0.05). At 
12 months, 24-h SBP change predictors were: baseline office SBP (OR 4.93 for 10 mm Hg SBP increment, 95% CI 1.01–24.1, 
p < 0.05) and 2 h-glucose (OR 1.47, 95% CI 1.08–2.00, p < 0.05). In ABPM responders, significant reduction of 2 h glucose 
was found as compared to the non-responders (–45.8 vs. –7.7 mg/dL, p < 0.005).
Conclusions: The RDN-POL Registry demonstrated moderate blood pressure decrease after RDN. The predictors of blood 
pressure reduction were diabetes, 2 h-glucose, and baseline office SBP. Analysis of ABPM responders indicates a probable 
positive impact of RDN on glycaemic control.
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INTRODUCTION
Percutaneous, catheter-based renal sympathetic denerva-
tion achieved by the application of discrete, low-dose ra-
diofrequency energy to the renal artery adventitia has been 
reported to reduce blood pressure (BP) by the impairment 
of renal sympathetic efferent and afferent signalling [1–3]. 
Both in the “first-in-man” Symplicity HTN-1 trial and in the 
randomised Symplicity HTN-2 study, significant reductions of 
the office blood pressure measurements were demonstrated. 
The lower changes observed in 24-h ambulatory BP monitor-
ing (ABPM) — not mandatory in the study protocol — raised 
some concerns about the probability of recruitment of subjects 
with pseudo-resistant hypertension and its potential impact 
on the results. Moreover, the recently published randomised 
Symplicity HTN-3 trial results did not confirm better reduction 
of BP after renal denervation in comparison to pharmacologi-
cal treatment, starting the discussion about the future of this 
method [4–6]. 
The Renal Denervation Polish Registry (RDN-POL Reg-
istry) was initiated independently on other registries and set 
up for the evaluation of the effects of the denervation proce-
dure on office and 24-h BP measurements in patients with 
proven resistant hypertension and declaring good treatment 
adherence (as assessed by the referring doctor), in a newly 
established net of eleven Polish centres equipped with the 
Symplicity renal denervation system.
METHODS
Inclusion criteria comprised: age 18–70 years, true resistant 
hypertension defined as systolic BP (SBP) of 160 mm Hg 
or greater (an average of three office BP readings) and mean 
of systolic daytime pressure confirmed in 24-h ABPM of 
135 mm Hg or greater, treatment with maximum tolerated and 
unchanged doses of at least three antihypertensive drugs (in-
cluding a diuretic) for a minimum of 4 weeks prior to screen-
ing, favourable anatomy of both renal artery trunks (minimal 
diameter of 4 mm and length of 20 mm) and an estimated 
glomerular filtration rate (eGFR) of at least 45 mL/min, using 
the Modification of Diet in Renal Disease (MDRD) study eq-
uitation [7]. All patients before the confirmatory ABPM were 
interviewed again about treatment adherence.
The exclusion criteria were as follows: a) renal artery ab-
normalities (significant renal artery stenosis, prior angioplasty 
or stenting, multiple renal arteries); b) known secondary 
hypertension: primary aldosteronism (based on plasma renin 
activity/aldosterone ratio), pheochromocytoma (based on 
urine methoxy catecholamine concentrations), coarctation of 
the aorta or Cushing disease (according to the local standard 
practice); c) myocardial infarction, unstable angina pectoris, 
or a cerebrovascular accident within 6 months of the screen-
ing visit or widespread atherosclerosis, with documented 
intravascular thrombosis or unstable plaques; d) chronic heart 
failure New York Heart Association (NYHA) class III or IV; 
e) type 1 diabetes mellitus; f) the presence of an implantable 
cardioverter defibrillator or pacemaker; f) treatment with 
any of the following medications: systemic corticosteroids, 
fludrocortisone, warfarin; g) any serious medical condition, 
which, in the opinion of the investigator, may adversely af-
fect the safety and/or effectiveness of the participant or the 
study (i.e. clinically significant peripheral vascular disease, 
abdominal aortic aneurysm, bleeding disorders such as 
thrombocytopenia, haemophilia, or significant anaemia, or 
arrhythmias such as atrial fibrillation, respiratory support); 
h) pregnancy current or planned within the follow-up (female 
participants of childbearing potential had to have a negative 
serum or urine human chorionic gonadotropin (pregnancy 
test prior to enrolment); i) known, unresolved history of drug 
overuse or alcohol addiction; and j) current enrolment in 
another investigational drug or device trial.
All patients provided written, informed consent and the 
study was approved by the institutional ethics committee.
Forty-seven patients were submitted to the Registry by 
11 centres. Forty-four of them with true-resistant hypertension 
and complete bilateral renal denervation were included into 
the database and have been followed-up for 12 months. Three 
patients were not entered: two of them had very low base-
line office SBP (140 and 133 mm Hg, respectively), and one 
patient underwent incomplete renal denervation (less than 
four ablations in each artery). In all patients, the daytime SBP 
levels in ABPM were higher than 135 mm Hg, confirming 
resistant hypertension; however, in eight of them the mean 
of three office SBP measurements was less than 160 mm Hg 
(151–159 mm Hg). The scientific committee decided not to 
exclude these patients from the registry. 
Follow-up data after 3, 6, and 12 months were obtained 
from 41, 43, and 42 patients, respectively. One patient died 
between 3- and 6-month visit due to intracranial haemor-
rhage, and another one did not agree to have a control visit 
at 12 months.
Study procedures
Office blood pressure measurements and ABPM, clinical 
evaluation, adverse event incidence and general chemistries 
(creatinine, sodium, potassium) were assessed at baseline and 
repeated on follow-up assessment at 1, 3, 6, and 12 months, 
excluding ABPM which was not obligatory at 1 month. Blood 
samples for all biochemical evaluations were taken after 
overnight fasting, and eGFR was calculated using the MDRD 
equation. Glucose concentrations were measured in a fasting 
state and in oral glucose tolerance test (OGTT) 2 h after 75 g 
glucose administration. OGTT was performed in 34 patients 
before and in 29 patients 6 months after the procedure. 
Haemoglobin A1c (HbA1c) level was assessed in 29 patients 
at baseline and in 33 patients at 6 months. 
Office BP measurements
Blood pressure was measured with the patient in the sitting 
position after a 5-min rest, using an automated device. Three 
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consecutive readings were performed. If the difference be-
tween readings was higher than 10 mm Hg, further measure-
ments were taken so as to obtain three consecutive consistent 
readings. The average of these three readings was recorded. 
Ambulatory BP measurements
In all patients, ambulatory BP measurements were recorded; 
readings were obtained every 15 min during the day (06:00– 
–22:00 h) and every 30 min during the night (22:00–06:00 h). 
Division on sleep and activity periods was made after the 
recoding based on data from patient diary. Recordings had to 
be repeated when less than 70% of the readings were valid. 
Renal denervation
The treatment catheter (Symplicity, Ardian Inc., Palo Alto, 
CA, USA) was introduced into each renal artery via femoral 
access. A detailed description of the procedure can be found 
elsewhere [1]. Briefly, discrete, radiofrequency ablations of 
8 watts or less were applied, lasting 2 min each, to obtain 
4–6 ablations separated both longitudinally and rotationally 
within each renal artery. During ablation, the catheter system 
monitored tip temperature and impedance, altering radi-
ofrequency energy delivery in response to a predetermined 
algorithm. The first two procedures performed in each site 
were supervised by one of two interventionalists from the co-
ordinating centre, who were experienced with the procedure. 
Statistical analysis
The results throughout are presented as mean and standard 
deviation except for the number of antihypertensive drugs, 
which is depicted as median and interquartile range given 
in brackets. For comparison between measures before and 
after denervation, t-test for variables with normal distribution 
and non-parametric Wilcoxon signed-rank test for variables 
without normal distribution was employed. Multivariate 
stepwise backward regression analysis of key characteristics 
that may predict increased SBP response was performed. 
Baseline variables entered into the model were: age, sex, of-
fice SBP, ABPM daytime SBP, body mass index, baseline heart 
rate (HR), number of antihypertensive medications, eGFR, 
hypercholesterolaemia, diabetes, glucose level in 2-h OGTT, 
and number of ablations. Data analysis was carried out using 
statistical application SAS System version 9.2.
RESULTS
Subjects’ characteristics
Forty-four patients (23 men, 21 women) with mean age 
52.3 ± 9.2 years were entered into the registry database. 
Baseline characteristics of these patients are shown in 
Table 1. Both office SBP and diastolic BP (DBP) were sig-
nificantly higher in patients with increased HR (HR over 
the mean of 80 bpm) as compared to subjects with HR 
below 80 bpm (181.7 ± 23.1 vs. 168.6 ± 11.9 mm Hg, 
p < 0.05 for SBP and 108.0 ± 18.1 vs. 94.6 ± 11.6 mm Hg, 
p < 0.005 for DBP). Office DBP was also increased in 
patients treated with mineralocorticoid receptor antagonist 
(105.8 ± 16.8 vs. 93.8 ± 12.1 mm Hg, p < 0.001) as well as 
in non-obese subjects (104.8 ± 17.6 vs. 94.7 ± 11.9 mm Hg, 
p < 0.05).
Mean 24-h SBP was elevated in non-dippers (160.8 
± 17.8 vs. 148.0 ± 14.3 mm Hg, p < 0.05) and in non-obese 
patients (159.2 ± 19.0 vs. 147.8 ± 12.6 mm Hg, p < 0.05). 
24-h DBP was higher in patients with increased HR 
(100 ± 16.1 vs. 84.4 ± 20.6 mm Hg, p < 0.05), non-obese 
patients (100.2 ± 17.5 vs. 80.7 ± 18.5 mm Hg, p < 0.001), 
and patients treated with mineralocorticoid receptor antago-
nist (98.5 ± 18.3 vs. 82.4 ± 19.4 mm Hg, p < 0.01). 
The median number of antihypertensive drugs was 
5.5 (interquartile range: 5.0–7.0). During the follow-up 
period, the maintenance of the antihypertensive regimen 
was required unless clinically indicated. Of note, 8 (18.6%) 
patients were on a reduced number of medications at 6-month 
Table 1. Clinical characteristics of the studied group
Males 23 (52%)
Age [years] 52.3 ± 9.2
Obesity (BMI > 30 kg/m2) 22 (50%)
eGFR (mL/min/1.73 m2) 83.1 ± 22.8
Diabetes
Diabetes — insulin treated
12 (27%) 
5 (42%) 
Hyperlipidaemia 23 (52%)
Office SBP [mm Hg] 173.7 ± 18.1
Office DBP [mm Hg] 99.8 ± 15.7
Ambulatory 24-h SBP [mm Hg] 153.5 ± 16.9
Ambulatory 24-h DBP [mm Hg] 90.4 ± 20.3
Ambulatory daytime SBP [mm Hg] 158.8 ± 16.8
Ambulatory daytime DBP [mm Hg] 96.2 ± 16.5
Ambulatory night-time SBP [mm Hg] 141.4 ± 21.3
Ambulatory night-time DBP [mm Hg] 83.0 ± 16.7
No. of antihypertensive medications 5.7 ± 1.4
Type of antihypertensive medication:
ACE inhibitor/ARB
Beta blocker
Aldosterone receptor antagonist
Diuretic
CCB 
AAB 
Other
59%/66%
95%
50%
100%
93%
50%
18%
Continuous variables are presented as means and standard deviations; 
AAB — alpha-adrenergic blocker; ACE — angiotensin converting 
enzyme; ARB — angiotensin receptor blocker; BMI — body mass index; 
CCB — calcium channel blocker; DBP — diastolic blood pressure; eGFR 
— estimated glomerular filtration ratio; SBP — systolic blood pressure
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follow-up visit and 11 (26.2%) patients at 12-month visit. In 
2 patients, minor changes within the same class of drugs were 
done. An increased number of drugs was reported in 2 (4.7%) 
patients at 6 months and in 1 (2.3%) patient at 1 year visit. 
All those modifications resulted in significant decrease of the 
median number of hypertensive drugs taken at 6 months 
(5.0, interquartile range: 5.0–6.0) and 1 year (5.0, interquar-
tile range: 4.0–6.0; p < 0.05 and p < 0.01, respectively, as 
compared to baseline). 
Procedure characteristics
Mean length and diameter of the renal artery trunk was 
35.9 mm/5.9 mm on the left, and 39.5 mm/5.8 mm on the 
right side. The successful procedure, defined as delivery of 
least four complete, 2-min energy applications to each renal 
artery, was performed in all 44 patients. The mean number 
of applications was 5.1 ± 0.6 per renal artery. During the 
procedure, significant vasovagal bradycardia requiring atro-
pine occurred in 12 (27%) patients. There were no any acute 
complications like artery dissection, abrupt closure, or access 
site pseudoaneurysm.
Office BP during the follow-up
Mean reductions of office SBP were –23.8 ± 32.1 mm Hg af-
ter 3 months (p < 0.001), –12.5 ± 23.4 mm Hg after 6 months 
(p < 0.005) and –12.6 ± 26.0 mm Hg after 1 year (p = 0.005), 
as presented in Figure 1. Additional subanalysis without 8 pa-
tients with baseline office SBP below 160 mm Hg showed 
similar reductions of SBP: –25.9 ± 33.3, –13.0 ± 23.0, and 
–13.0 ± 27.7 mm Hg (all significant). The non-responders 
rate (with SBP reduction less than 10 mm Hg) was 46.5% at 
6 months and 38% at 12 months. SBP decrease at 12 months 
was higher in obese patients as compared to non-obese 
subjects (–20.3 ± 17.4 mm Hg vs. –4.1 ± 31.3 mm Hg, 
p < 0.05). 
Mean reductions of office DBP were –10.0 ± 19.7 mm Hg 
after 3 months (p < 0.001), –4.6 ± 16.5 mm Hg after 
6 months (p = NS), and –6.1 ± 14. mm Hg after 1 year 
(p < 0.01). Significant difference in DBP reduction at 
12 months was detected between patients with increased 
and normal HR (–12.8 ± 14.0 mm Hg vs. –2.5 ± 13.0 mm Hg, 
p < 0.01).
The presence of diabetes was the only predictor of the 
SBP improvement at 6 months (OR 9.6, 95% CI 1.4–66.5, 
p < 0.05). At 12 months, no significant predictor of SBP 
response was found. 
Significant reductions of pulse pressure were observed 
at 3 months (–13.8 ± 18.9 mm Hg, p < 0.0001), 6 months 
(–7.9 ± 18.1 mm Hg, p < 0.01), and 1 year (–6.4 ± 24.3 mm Hg, 
p < 0.05) after renal denervation.
24-hour ABPM results at 6 months and 1 year
Mean change of 24-h SBP at 6 months was –8.3 ± 19.1 mm Hg 
(p < 0.01), and –4.6 ± 18.5 mm Hg (p = NS) at 
12 months. The changes of daytime SBP were significant at 
6 months (–10.6 ± 20.1 mm Hg, p < 0.0001) and 12 months 
(–7.4 ± 20.1 mm Hg, p < 0.05) whereas the reduction of 
night-time SBP was not significant (data not shown). The 
ABPM non-responders rate (with 24-h SBP reduction less 
than 5 mm Hg) was 45% at 6 months and 55% at 12 months.
Mean change of 24-h DBP at 6 months was –2.9 ± 17.5 
(p < 0.05) and –1.2 ± 17.3 mm Hg (p = NS) at 12 months. The 
reduction of daytime DBP was –6.3 ± 12.5 mm Hg (p < 0.01) 
at 6 months and –4.1 ± 13.9 mm Hg (p = NS) at 1 year. The 
night-time DBP changes were non significant (not presented).
Twenty-four-hour SBP and DBP reductions were signifi-
cant in patients with increased baseline HR both at 6 months 
(–15.9 ± 19.9 mm Hg, p < 0.01/–10.2 ± 14.3 mm Hg, 
p < 0.05) and at 1 year (–11 ± 18.2 mm Hg/–7.4 ± 13.0 mm Hg, 
both p < 0.05). In multivariate analysis, increased 2-h 
glucose concentration measured in OGTT was the only 
predictor of 24-h SBP response at 6 months (OR 1.24 for 
each 10 mg/dL increase in glucose concentration, 95% CI 
1.04–1.48, p < 0.05). At 12 months, the predictors of 24-h 
SBP decrease were: higher baseline office SBP (OR 4.93 
for 10 mm Hg increment in SBP, 95% CI 1.01– 24.1, 
p < 0.05) and increased 2-h glucose in OGTT (OR 1.47 for 
each 10 mg/dL increase in glucose concentration, 95% CI 
1.08–2.00, p < 0.05)
Heart-rate changes
Significant decrease in HR was observed at 6 months 
(–5.2 ± 15.4 bpm, p < 0.05) but non-significant at 
12 months in all subjects (–2.3 ± 12.4 bpm, p = NS). HR 
reduction after renal denervation was related to baseline 
HR. In patients with increased baseline HR, the HR reduc-
tions were –17.3 ± 14.4 bpm (p < 0.005) at 6 months and 
Figure 1. The mean changes of systolic and diastolic 
blood pressure (BP) after percutaneous renal denervation; 
*p < 0.0001; **p < 0.005; ***p < 0.01
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–11.9 ± 7.8 bpm (p < 0.0001) at 12 months, and they were 
significantly higher than those seen in subjects with baseline 
HR below 80 bpm (p for comparison < 0.0001 at 6 and at 
12 months).
Metabolic and kidney parameters changes  
at 6 months
There were no significant changes in metabolic parameters 
at 6 months after renal denervation: non significant decrease 
in 2-h glucose concentration in OGTT (–14.2 ± 56.6 mg/dL), 
slight increase of fasting plasma glucose (5.6 ± 4.7 mg/dL), 
and no change in HbA1c level were observed (0.1 ± 0.7%). 
Significant difference in HbA1c change was observed only be-
tween younger (< 55 years) and older patients (–0.2 ± 0.5% 
vs. 0.5 ± 0.7%, respectively, p < 0.05). However, a remark-
able relationship between the changes in glucose metabolic 
parameters and ABPM response was found. In subgroups 
of ABPM-responders, a significant reduction of 2-h glucose 
in OGTT was found as compared to the non-responders 
(–41.7 ± 47.0 mg/dL vs. 17.8 ± 50.7 mg/dL, p < 0.005). 
Plasma fasting glucose concentration increased in ABPM 
non-responders and remained stable in the responders sub-
group, as presented in Table 2.
Mean changes of eGFR were 4.6 ± 21.6; 6.4 ± 21.3 and 
1.2 ± 21.9 mL/min per 1.73 m2 at 3, 6, and 12 months, re-
spectively. The change of eGFR was not associated with BP 
response. No significant renal artery stenosis was found on 
ultrasonography at 6 months.
DISCUSSION
The results of the RDN-POL Registry show that in patients with 
confirmed in ABPM resistant hypertension, catheter-based 
renal denervation therapy causes moderate reduction in office 
SBP. The reductions of pulse pressure were also significant, but 
the changes of DBP were rather modest. Additionally, ABPM 
recordings showed only small BP decrease at 6 months, and 
no significant change at 1 year after renal denervation. In initial 
clinical trials — randomised Symplicity HTN-2 and non-ran-
domised Symplicity HTN-1 study — observed reductions in 
office SBP were about 30 mm Hg [2, 3]. However, in contrast 
to our registry, neither protocol required ABPM recordings for 
“true-resistance” confirmation. The results in ABPM measure-
ments are less impressive but are consistent with the recently 
published, largest randomised, sham-controlled Symplicity 
HTN-3 trial, including 535 patients with ABPM-confirmed 
resistant hypertension [4]. In the Symplicity HTN-3 trial, the 
decrease of SBP in ABPM at 6 months was lower than in our 
Registry (–6.75 mm Hg vs. –8.3 mm Hg).
The RDN-POL Registry reflects real-world patient results 
rather than first clinical trials data, like those obtained in the 
Symplicity HTN-1 and Symplicity HTN-2 trials. For com-
parison, in a report by Id et al. [8] the 6-month reduction in 
office SBP in 54 patients after bilateral denervation of single 
renal arteries was 16.6 mm Hg. The change in 24-h SBP was 
identical to our result (–8.3 mm Hg). Similarly, Volz et al. 
[9] reported a 17-mm Hg reduction in office SBP, but only 
a 6-mm Hg change in ABMP recordings. Recent meta-analysis 
of 7 randomised-control studies demonstrated a 16.5-mm Hg 
decrease of office and 9.2-mm Hg of 24-h SBP [10]. By con-
trast, Mahfoud et al. [11] demonstrated excellent office SBP 
reduction by 23.7 and 27.3 mm Hg after 6 and 12 months 
in 303 patients with true-resistant hypertension. However, in 
that study the 24-h SBP changes were also less pronounced 
(–10 and –11.7 mm Hg, respectively).
In our report, the strongest predictors of SBP response 
evaluated in ABPM recordings were baseline office SBP and 
baseline 2-h glucose concentration in OGTT. Every 10-mm Hg 
increase of baseline office SBP was associated in almost 
5-fold higher probability of significant SBP reduction in ABPM 
after 1 year. Notably, every 10-mg/dL rise in 2-h glucose level 
in OGTT increased that probability by 24% at 6 months and 
by 47% at 12 months after renal denervation. Moreover, the 
2-h glucose concentration in OGTT was substantially reduced 
after 6 months in the subgroup of ABPM-responders. It sup-
ports the hypothesis that efficient renal denervation may 
also diminish insulin resistance resulting from sympathetic 
Table 2. Changes (means and standard deviations) in fasting and 2-h glucose concentration in relation to 24-h systolic blood 
pressure response
Variable ABPM — responders ABPM — non-responders P
Fasting plasma glucose [mg/dL]:
At baseline
At 6 months
Change 
96.2 ± 18.1
95.4 ± 19.5
–0.4 ± 20.9
95.7 ± 22.1
111.7 ± 40.2
15.3 ± 25.9*
NS
NS
NS (0.054)
2-h glucose in OGTT [mg/dL]:
At baseline
At 6 months
Change
186.5 ± 68.3
149.5 ± 51.9
–41.7 ± 47.0*
117.3 ± 45.6
135.4 ± 49.8
17.8 ± 50.7
< 0.005
NS
< 0.005
*p < 0.01; ABPM — ambulatory blood pressure monitoring; OGTT — oral glucose tolerance test
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adrenergic hyperactivity. It has been shown that inhibition 
of the sympathetic nervous system by moxonidine improved 
glucose metabolism by decreasing glucagon secretion and 
increasing skeletal blood flow with less glycogenolysis and 
gluconeogenesis [12]. It confirmed a pathophysiological 
association between the central nervous system and insulin 
resistance. Our data are consistent with the results of two 
previously published trials, suggesting a beneficial effect of 
renal denervation on indices of glucose metabolism [13, 14]. 
Increased SBP was an independent predictor of BP reduc-
tion in the abovementioned study of Mahfoud et al. [11] and 
in Symplicity HTN-3, where also aldosterone antagonist use 
and non-use of vasodilators remained significant predictors 
in multivariate analysis [15]. In other trial, higher 24-h SBP 
predicted BP improvement [16]. In the presented registry, 
such a correlation was not found, which may be due to the 
small patient cohort. The report of Zuern et al. [17] also sug-
gested that baroreflex sensitivity test may predict hypertension 
response after renal denervation.
Interestingly, in our patients with true-resistant hyperten-
sion, renal denervation was also accompanied by a reduction 
of HR, especially in patients with baseline HR over 80 bpm. 
Moreover, 24-h SBP and DBP reductions were more significant 
in patients with increased baseline HR. It confirms that increased 
HR reflects excessive sympathetic nervous system activity and 
may indicate patients deriving benefit from renal denervation. 
Our study confirmed the safety of percutaneous renal 
denervation. No access site complications and no serious 
procedure-related complications were reported. Also, small 
changes in eGFR during the follow-up period confirmed the 
safety of the procedure. 
Limitations of the study
The RDN-POL Registry has a number of limitations that may 
influence its results. Firstly, in our trial, about 25% of patients 
changed their recommended antihypertensive drugs regimen 
during the follow-up period, in most cases by reduction of the 
number of drugs taken. It could increase BP results obtained 
at follow-up visits and diminish the effect of renal denervation 
on the hypertension treatment. However, subanalysis of the 
patients maintained on baseline drugs regimen did not reveal 
better BP response after renal denervation (not presented). 
For comparison, in the Symplicity HTN-3 trial, 40% of pa-
tients changed the medications after the procedure, and the 
reduction of the BP was not associated with the hypertension 
treatment modification.
Secondly, this is a non-randomised, single-arm study 
with a modest sample size, which does not allow us to draw 
definitive conclusions. 
Thirdly, it should be mentioned that the majority of sites 
(9 of 11) were not experienced in renal denervation procedure 
before entering into the registry. Only two sites had partici-
pated previously in the Symplicity HTN-1 or HTN-2 trials. As 
no roll-in phase had been introduced, procedures were 
performed by operators who were experienced with endovas-
cular techniques, but who were novices in renal denervation 
technique. Despite the majority of the procedures being su-
pervised by the experienced proctor, this fact could have had 
impact on the level of the completeness and effectiveness of 
the procedures. The results of single site studies and registries 
demonstrated better results of renal denervation procedures 
performed by experienced operators [18, 19].
Finally, it may be hypothesised that the maximum num-
ber of 6 discrete applications as limited by the protocol was 
probably insufficient. As Kandzari et al. [15] demonstrated in 
their Symplicity HTN-3 analysis, the BP reduction was linearly 
correlated with the higher number of ablations and with en-
ergy delivery in a four-quadrant pattern. The best results were 
achieved in subjects with more than 12 applications done 
in both arteries. It should also be emphasised that no tests 
are available allowing assessment of proper wall contact and 
effective destruction of renal nerves during or after the pro-
cedure. In tortuous renal arteries it is more difficult to obtain 
appropriate contact of the catheter’s tip with the vessel wall 
assuring proper energy delivery to the nerve fibres located 
in the adventitia. Probably, the new helical multi-electrode 
catheter will improve the electrodes apposition and provide 
better vessel wall heating. 
CONCLUSIONS
In conclusion, the RDN-POL Registry demonstrated that the 
reductions in office BP up to 30 mm Hg observed in first 
clinical studies may be difficult to obtain in real-world pa-
tients. The office BP improvement is moderate, and the renal 
denervation is rather a complementary method of treatment 
than an alternative to the standard pharmacotherapy. Renal 
denervation also decreases HR, especially in patients with 
baseline increased pulse rate. Interestingly, a subanalysis of 
patients with adequate BP response in ABPM indicates that 
renal denervation may have a positive impact on glycaemic 
control. Further studies in this field of research are warranted.
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S t r e s z c z e n i e
Wstęp i cel: Celem niniejszej pracy była ocena skuteczności przezskórnej denerwacji nerek (RDN) u pacjentów z prawdziwie 
opornym nadciśnieniem tętniczym oraz przedstawienie wyników Polskiego Rejestru Denerwacji — RDN-POL.
Metody: U 44 pacjentów z prawdziwie opornym nadciśnieniem tętniczym (23 mężczyzn, mediana wieku 55 lat) ze skurczowym 
ciśnieniem tętniczym (SBP) w 24-godzinnym pomiarze ambulatoryjnego ciśnienia tętniczego (ABPM) ≥ 135 mm Hg, leczonych 
co najmniej 3 lekami hipotensyjnymi, w tym diuretykiem, wykonano RDN. Okres obserwacji wyniósł 12 miesięcy po zabiegu.
Wyniki: Zaobserwowano średnią redukcję ciśnienia tętniczego w pomiarach gabinetowych o –23,8/–10,0; –12,5/–4,6 i –12,6/ 
/–6,1 mm Hg po odpowiednio 3, 6 i 12 miesiącach obserwacji (wszystkie znamienne statystycznie oprócz zmiany rozkur-
czowego ciśnienia tętniczego po 6 miesiącach). Obecność cukrzycy była jedynym predyktorem redukcji SBP w pomiarach 
gabinetowych po 6 miesiącach (OR 9,6; 95% CI 1,4–66,5; p < 0,05). Średnia redukcja SBP w ciągu doby w ABPM wyniosła 
–8,3 mm Hg po 6 miesiącach oraz –4,6 mm Hg po 12 miesiącach od zabiegu. Zwiększone stężenie glukozy w doustnym 
teście obciążenia glukozą okazało się predyktorem redukcji SBP w ABPM po 6 miesiącach (OR 1,24 na każdy wzrost glikemii 
o 10 mg/dl; 95% CI 1,04–1,48; p < 0,05). Po 12 miesiącach predyktorami zmiany SBP w pomiarze ABPM były: wyjściowe 
SBP w pomiarach gabinetowych przed zabiegiem (OR 4,93 na każdy wzrost SBP o 10 mm Hg, 95% CI 1,01–24,1; p < 0,05) 
i stężenie glukozy w teście obciążenia glukozą (OR 1,47; 95% CI 1,08–2,00; p < 0,05). U osób z uzyskaną co najmniej 
5-mm Hg redukcją SBP w ABPM (tzw. responders), zaobserwowano istotne zmniejszenie glikemii w teście obciążenia glukozą 
w porównaniu z osobami bez spadku SBP w ABPM (–45,8 vs. –7,7 mg/dl; p < 0,005).
Wnioski: Wyniki rejestru RDN-POL wskazują na umiarkowaną redukcję ciśnienia tętniczego uzyskaną po RDN. Predyktorami 
poprawy kontroli ciśnienia tętniczego okazały się: obecność cukrzycy, glikemia w teście obciążenia glukozą i wartość SBP 
przed zabiegiem. Analiza osób z istotną redukcją SBP w pomiarach ABPM wskazuje na potencjalny korzystny wpływ RDN 
na poprawę profilu glikemicznego.
Słowa kluczowe: oporne nadciśnienie tętnicze, denerwacja nerek, rejestr, cukrzyca, współczulny układ nerwowy
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